Company Encyclopedia
View More
name
Aligos Therapeutics
ALGS.US
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus.
1.946 T
ALGS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking290/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-141.82%E
    • Profit Margin-3267.65%E
    • Gross Margin-3130.36%E
  • Growth ScoreD
    • Revenue YoY-55.88%E
    • Net Profit YoY-12.36%D
    • Total Assets YoY24.13%A
    • Net Assets YoY43.39%A
  • Cash ScoreD
    • Cash Flow Margin-3.06%D
    • OCF YoY-55.88%E
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio34.56%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sio Capital Management LLC Increases Stock Position in Aligos Therapeutics, Inc. $ALGS

    Sio Capital Management LLC increased its stake in Aligos Therapeutics by 85.9% in Q2, owning 5.50% of the company. Aligos Therapeutics, a clinical-stage biopharmaceutical firm, has mixed analyst ratings with a consensus 'Hold' and a $50 price target. The stock recently traded at $9.30, with a market cap of $57.20 million. Despite a negative earnings report, the company continues to develop treatments for viral and liver diseases.

    Market Beat·
    US
    ALGS
    +2.23%
    Market Beat·
    US
    ALGS
    +2.23%

    Aligos Therapeutics: Strong Buy Rating Backed by Promising Liver Disease Treatments and Strategic Positioning

    Patrick Trucchio from H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics, with a $50 price target. The company's focus on chronic HBV and MASH shows promising results, with lead drug pevifoscorvir sodium potentially replacing standard HBV treatments. ALG-055009 has shown strong efficacy in Phase 2 trials. Aligos has a solid cash position and upcoming milestones, supporting its leadership in liver disease innovation.

    Tip Ranks·
    US
    ALGS
    +2.23%
    Tip Ranks·
    US
    ALGS
    +2.23%

    Aligos Therapeutics Grants Stock Options to New Employees Under Inducement Plan

    Aligos Therapeutics Inc. has granted non-qualified stock options to purchase 23,600 shares to new employees under its 2024 Inducement Plan. The options have an exercise price set at the closing price of Aligos' common stock on November 11, 2025, and will vest over four years. This news was originally published by Aligos Therapeutics via GlobeNewswire on November 14, 2025.

    Reuters·
    US
    ALGS
    +2.23%
    Reuters·
    US
    ALGS
    +2.23%

    Aligos Therapeutics Reports Positive 96-Week Data for Pevifoscorvir Sodium in Chronic Hepatitis B

    Aligos Therapeutics Inc. reported positive 96-week data for pevifoscorvir sodium, a treatment for chronic hepatitis B, at The Liver Meeting® 2025. The results indicated effective suppression of HBV DNA and reduced HBV antigen levels in treatment-naive subjects. Presentations included an oral report by Professor Man-Fung Yuen and preclinical data on ALG-001075, which inhibits cccDNA formation. The company also noted advancements in its HBV antisense oligonucleotide program.

    Reuters·
    US
    ALGS
    +2.23%
    Reuters·
    US
    ALGS
    +2.23%

    Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating

    H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Aligos Therapeutics, maintaining a price target of $50. The rating is supported by the company's strategic execution and promising pipeline, particularly its lead program, pevifoscorvir sodium, currently in Phase 2 trials for chronic hepatitis B. The drug shows potential for significant revenue, estimated at over $1.8 billion annually. Aligos is also exploring its ALG-055009 program, enhancing its strategic positioning in the market.

    Tip Ranks·
    US
    ALGS
    +2.23%
    Tip Ranks·
    US
    ALGS
    +2.23%
    © 2025 Longbridge｜Disclaimer